Trump Executive Order Tracker | Akin Public Policy and Lobbying

Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve (Trump EO Tracker)

August 13, 2025

Reading Time : 2 min
Trump Executive Order Tracker | Akin Public Policy and Lobbying

The Executive Order aims to bolster the resilience of the United States’s pharmaceutical supply chain by stockpiling Active Pharmaceutical Ingredients (“APIs”) for critical medicines in the Strategic Active Pharmaceutical Ingredients Reserve (“SAPIR”) and encouraging the domestic production and procurement of such APIs.

The EO includes several directives and deadlines.

  • Section 2(a): Within 30 days of the EO, the Office of the Assistant Secretary for Preparedness and Response (“ASPR”) within the Department of Health and Human Services must create a list “of approximately 26 drugs that are especially critical to the health and security interests of the Nation (the critical drugs).” The ASPR must also create an accounting of funds available to finance and maintain the SAPIR repository with a 6-month supply of APIs for critical drugs referenced in Section 2(c). The list and accounting must be provided to the Director of the Office of Management and Budget (“OMB”), who will assist with repurposing available funds.
  • Section 2(b): Within 120 days of the EO, and subject to the availability of funds identified in Section 2(a), the ASPR must prepare the existing SAPIR repository to begin receiving and maintaining APIs.
  • Section 2(c): Subject to the availability of funds identified in Section 2(a), the ASPR must secure a 6-month supply of APIs needed to make critical drugs, prioritizing APIs manufactured domestically. APIs must be placed within the SAPIR repository within 30 days after the repository is certified to receive and maintain APIs.
  • Section 3(a): Within 90 days of the EO, the ASPR must update its 2022 list of 86 essential medicines and medical countermeasures and provide it to the Assistant to the President and Homeland Security Advisor (“APHSA”), the Assistant to the President for Economic Policy (“APEP”), and OMB. The update should include a plan to obtain APIs for drugs on the updated essential medicines list from domestic manufacturers, where possible, and to store and maintain a 6-month supply of those APIs.
  • Section 3(b): The plan in Section 3(a) must also include a proposal to open a second SAPIR site within one year of the EO.

Additional Documentation

Share This Insight

Related Content

Trump Executive Order Tracker

The significant number of executive orders published by the Trump Administration cut across dozens of industries and areas of law. This searchable tool breaks down the orders and their impacts on specific industries and with in-depth analysis of specific orders.

Previous Entries

Trump Executive Order Tracker

June 3, 2026

Directs executive branch agencies to expand and implement Schedule Policy/Career, an excepted-service personnel category for career federal employees in policy-influencing positions. Transfers designated positions into Schedule Policy/Career, making employees in those roles subject to streamlined removal procedures for poor performance or misconduct while retaining merit-based hiring requirements. Amends civil service regulations, requires agencies to identify additional policy-influencing positions for potential transfer, and establishes new performance award mechanisms to incentivize high-performing employees.

...

Read More

Trump Executive Order Tracker

May 29, 2026

The Executive Order (“EO”) directs the alignment of the U.S. core childhood vaccine schedule with the best practices of peer, developed countries, while preserving access to vaccines and protecting religious freedoms and enforcing legal protections for parents. Based on a scientific assessment completed by HHS pursuant to a Presidential Memorandum dated December 5, 2025, the order notes that the U.S. currently recommends more childhood vaccines than any peer nation and identified a set of consensus vaccines consistently recommended across all peer countries. The order directs the Centers for Disease Control and Prevention (“CDC”) and its Advisory Committee on Immunization Practices (ACIP) to review the scientific assessment and take appropriate steps to update the childhood and adolescent vaccine schedule, while providing maximum flexibility to parents and doctors regarding the timing and sequencing of routine immunizations. Additionally, all immunizations on the ACIP-recommended schedule and adopted by the CDC must continue to be covered without cost sharing by private insurance, Medicaid, the Children’s Health Insurance Program, and the Vaccines for Children Program. The order also reaffirms the Administration’s commitment to fulfilling all legal obligations with respect to parental authority, religious freedom, disability accommodations, and equal protection under the law.

...

Read More

Trump Executive Order Tracker

May 1, 2026

Expands upon Executive Order 14380 that established a national emergency regarding Cuba due its threat to U.S. national security by directing the Department of State and Treasury to block U.S. trade with foreign persons designated for operating in specified sectors of the Cuban economy, imposing immigration penalties and suspending entry for designated individuals associated with the Cuban government as determined by the Department of State, and directing the Treasury Department to sanction foreign financial institutions.

...

Read More

Trump Executive Order Tracker

April 30,2026

Grants Bridger Pipeline Expansion LLC a Presidential permit to construct and operate a cross-border oil pipeline in Montana, subject to federal oversight, compliance with all applicable laws, and conditions on modification, inspection, reporting, and potential government control or removal.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.